{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","spread":"0.5","upperLimit":"71.6","value":"20.0"},{"groupId":"OG001","lowerLimit":"6.4","spread":"6.4","upperLimit":"47.6","value":"22.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"CBR was defined as percentage of participants who had BOR of CR, PR, or durable SD (SD duration \\>=23 weeks since the first dose of study treatment) divided by number of participants in analysis set. CBR was assessed by an investigator based on RECIST v1.1 for non-HGG participants or RANO for HGG participants. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \\<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with recurrent or refractory solid tumors received lenvatinib 8 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily in cycle 1 (each cycle was 28 days) until the occurrence of PD, clinical benefit, development of unacceptable toxicity leading to withdrawal from the study, study discontinuation or for a maximum of 18 cycles (each cycle was 28 days) whichever occurred first.","id":"OG000","title":"Phase 1: Lenvatinib 8 mg/m^2 + Everolimus 3 mg/m^2"},{"description":"Participants with recurrent or refractory solid tumors received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily in cycle 1 (each cycle was 28 days) until the occurrence of PD, clinical benefit, development of unacceptable toxicity leading to withdrawal from the study, study discontinuation or for a maximum of 18 cycles (each cycle was 28 days) whichever occurred first.","id":"OG001","title":"Phase 1: Lenvatinib 11 mg/m^2 + Everolimus 3 mg/m^2"}],"paramType":"NUMBER","populationDescription":"SAS included all participants who received at least 1 dose of study drug (lenvatinib or everolimus).","reportingStatus":"POSTED","timeFrame":"From first dose of study drug until PD or death, whichever occurred first (up to 16.5 months)","title":"Phase 1: Clinical Benefit Rate (CBR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}